# Nuclide record f-radioligand-therapy (section). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/fronts/f-radioligand-therapy/>
  a schema:DefinedTerm ;
  nuclide:kind "section" ;
  schema:identifier "f-radioligand-therapy" ;
  schema:name "Radioligand therapy"@en ;
  schema:description "Radioligand therapy attaches a radioactive particle to a molecule that homes in on a tumour, so the radiation is delivered from the inside of the cancer rather than from an external beam."@en ;
  schema:url <https://nuclide.cc/fronts/f-radioligand-therapy/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf>, <https://www.nejm.org/doi/10.1056/NEJMoa2107322>, <https://pubmed.ncbi.nlm.nih.gov/42570199/>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC13458634/> ;
  nuclide:related <https://nuclide.cc/fronts/f-molecular-imaging/>, <https://nuclide.cc/fronts/f-alpha-therapy/>, <https://nuclide.cc/fronts/f-dosimetry/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/lung-net/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/lu177-radioligand-therapy/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/peptide-drug-conjugate/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/sstr-pet/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/drugs/itm-11/>, <https://nuclide.cc/drugs/fap-2286/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/advanced-accelerator-applications/>, <https://nuclide.cc/companies/point-biopharma/>, <https://nuclide.cc/companies/lantheus/>, <https://nuclide.cc/companies/itm/>, <https://nuclide.cc/companies/telix/> ;
  nuclide:terms <https://nuclide.cc/terms/prrt-term/>, <https://nuclide.cc/terms/psa50/>, <https://nuclide.cc/terms/mcrpc-mhspc/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/trials/splash/>, <https://nuclide.cc/trials/psmaddition/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-vision-nejm-2021/>, <https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/>, <https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/> .